Zhang, Yinqiang
Li, Chenggong
Du, Mengyi
Jiang, Huiwen
Luo, Wenjing
Tang, Lu
Kang, Yun
Xu, Jia
Wu, Zhuolin
Wang, Xindi
Huang, Zhongpei
Zhang, Yanlei
Wu, Di
Chang, Alex H. http://orcid.org/0000-0002-7572-309X
Hu, Yu http://orcid.org/0000-0002-2815-4568
Mei, Heng http://orcid.org/0000-0001-7941-2443
Funding for this research was provided by:
National Science Foundation of China | Key Programme (No.2019YFC1316203, No.2019YFC1316204)
National Natural Science Foundation of China (No.81873434)
Article History
Received: 23 November 2022
Revised: 3 March 2023
Accepted: 27 March 2023
First Online: 25 April 2023
Competing interests
: AHC is a founding member of Shanghai YaKe Biotechnology Ltd, a biotechnology company focusing on research and development of tumor cellular immunotherapy. YLZ is employed in Shanghai YaKe Biotechnology Ltd, DW is employed in Beijing GoBroad Hospital Management Co. Ltd and the other authors have declared that no conflict of interest exists.